Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) is reporting third quarter financial results on Thursday 12th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, OPNT is expected to report 3Q20 loss of $ 0.21 per share from revenue of $ 7.76 million.
For the full year, analysts anticipate top line of $ 27.39 million, while looking forward to loss of $ 0.83 per share bottom line.
Previous Quarter Performance
Opiant Pharmaceuticals, Inc. disclosed loss for the second quarter of $ 0.05 per share, from the revenue of $ 6.31 million. The quarterly revenues declined 6.93 percent compared with the same quarter last year. According to street consensus, OPNT was expected to report 2Q20 loss of $ 0.24 per share from revenue of $ 6.08 million. The bottom line results beat street analysts by $ 0.19 or 79.17 percent, at the same time, top line results outshined analysts by $ 0.23 million or 3.78 percent.
Stock Performance
Shares of Opiant Pharmaceuticals, Inc. traded up $ 0.36 or 4.97 percent on Wednesday, reaching $ 7.60 with volume of 30.50 thousand shares. Opiant Pharmaceuticals, Inc. has traded high as $ 8.00 and has cracked $ 7.26 on the downward trend
The closing price of $ 7.60, representing a 6.63 % increase from the 52 week low of $ 6.79 and a 60.29 % decrease over the 52 week high of $ 18.23.
The company has a market capital of $ 32.36 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Opiant Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 877-407-0792 (United States) or 201-689-8263 (International), when prompted, enter passcode 13712206 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.opiant.com
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; eating disorders, including bulimia nervosa and binge eating disorders; alcohol use disorders; acute cannabinoid overdose; opioid use disorders; and a heroin vaccine.
